FATE — Fate Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $486.06m
- $102.52m
- $63.53m
- 26
- 16
- 43
- 18
Annual cashflow statement for Fate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -98.1 | -173 | -212 | -282 | -161 |
| Depreciation | |||||
| Non-Cash Items | 9.14 | 144 | 41.3 | 54.5 | -8.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.64 | -12.8 | 2.1 | -34.7 | 19.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -83.2 | -39.2 | -163 | -248 | -132 |
| Capital Expenditures | -7.39 | -4.93 | -50.7 | -35.6 | -6.15 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -150 | -156 | -273 | 202 | 119 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -157 | -161 | -324 | 167 | 113 |
| Financing Cash Flow Items | 0 | 0.49 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 150 | 283 | 453 | 9.21 | 0.085 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -90.7 | 82.5 | -33.8 | -72.3 | -19.5 |